MEDSCI (02415) announced its interim results for 2025, reporting revenue of RMB 125 million, representing a year-on-year increase of 13.2%. Net profit reached RMB 13.239 million, surging 5238.3% compared to the same period last year. Basic earnings per share stood at 2.45 cents, with the company proposing an interim dividend of HK 1.1 cents per share. During the period, total revenue grew year-on-year, primarily driven by the recovery of the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies toward evidence-driven marketing models, which boosted demand for precision omnichannel marketing solutions.